Bedaquiline Access

NTCA has been alerted that the Johnson & Johnson Patient Assistance Foundation, Inc. Patient Assistance Program (“JJPAF Program”) will be discontinued on January 1, 2025. As a result, a new program — the Johnson & Johnson Patient Assistance Program (“J&JPAP”), has established a program to support the acquisition of SIRTURO® (Bedaquiline or BDQ).

The NEW application for under- and uninsured patients who are prescribed SIRTURO/BDQ is available here.

This page will be updated as NTCA learns more about this new process and other avenues available for medication acquisition.